News Releases

Month Year

Month Year

Investor Alerts

Jun 28, 2022

IDEAYA Announces Development Candidate Nomination of a Potential First-in-Class Pol Theta Helicase Inhibitor in Collaboration with GSK
Jun 8, 2022

IDEAYA Biosciences to Present at the 2022 Jefferies Global Healthcare Conference
May 10, 2022

IDEAYA Biosciences, Inc. Reports First Quarter 2022 Financial Results and Provides Business Update
May 3, 2022

IDEAYA Biosciences to Participate in Investor Conferences in May 2022
May 2, 2022

IDEAYA Biosciences Receives Orphan Drug Designation for Darovasertib, a PKC Inhibitor, for the Treatment of Uveal Melanoma
Apr 6, 2022

IDEAYA Biosciences Appoints Catherine Mackey, Ph.D., to its Board of Directors
Mar 15, 2022

IDEAYA Biosciences, Inc. Reports 2021 Financial Results and Provides Business Update
Mar 15, 2022

IDEAYA Biosciences Reports IDE397 Interim Phase 1 Clinical Data
Mar 14, 2022

IDEAYA and Pfizer Expand Clinical Trial Collaboration and Supply Agreements for Evaluation of Darovasertib and Crizotinib Combination in Metastatic Uveal Melanoma and Additional cMET-Driven Tumors
Mar 8, 2022

IDEAYA Biosciences Announces Investor Webcast to Report Interim IDE397 Phase 1 Clinical Data and Corporate Update

Show per page